Physician profile
Andrew Easow
NPI 1700291473
$10,109.43
in general payments reported to CMS, 2019-2025
27 companies · $593 in 2025
The $593 reported for 2025 was more than what a typical Critical Care Medicine (Internal Medicine) provider received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,131 · 2020: $902 · 2021: $337 · 2022: $242 · 2023: $5,300 · 2024: $604 · 2025: $593.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $3,216 · Food and Beverage: $2,135 · Travel and Lodging: $1,147.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $3,216.12 |
| Food and Beverage | $2,134.60 |
| Travel and Lodging | $1,147.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $4,263.09 | 2023 | Ion, Da Vinci Surgical System |
| Astrazeneca Pharmaceuticals Lp | $1,258.23 | 2022-2025 | Breztri, Tagrisso, Airsupra |
| Glaxosmithkline, LLC. | $1,005.60 | 2019-2025 | Arexvy, Trelegy Ellipta, Nucala |
| Boehringer Ingelheim Pharmaceuticals, INC. | $624.75 | 2019-2020 | |
| Covidien Lp | $546.28 | 2020 | |
| Bard Access Systems, INC. | $250.41 | 2019-2020 | |
| Daiichi Sankyo INC. | $247.44 | 2021-2023 | Injectafer |
| Insmed, INC. | $196.36 | 2019 | |
| Astellas Pharma US INC | $186.95 | 2025 | |
| United Therapeutics Corporation | $185.36 | 2019-2025 | Tyvaso |
| Actelion Pharmaceuticals US, INC. | $157.60 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $130.00 | 2023 | Libtayo |
| Gilead Sciences, INC. | $126.00 | 2024 | Veklury |
| Janssen Pharmaceuticals, INC | $125.00 | 2019 | |
| Jazz Pharmaceuticals INC. | $123.89 | 2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amag Pharmaceuticals, INC. | $107.84 | 2021 | |
| Pharmacosmos Therapeutics INC. | $106.41 | 2021 | |
| Grifols USA, LLC | $94.10 | 2022-2025 | Prolastin-C Liquid |
| Genzyme Corporation | $92.10 | 2019 | |
| Pulmonx Corporation | $70.34 | 2020-2025 | Chartis Catheter, Zephyr Endobronchial Valve, Zephyr Delivery Catheter |
| Verona Pharma, INC. | $58.31 | 2025 | Ohtuvayre |
| Inogen, INC. | $36.51 | 2025 | |
| Csl Behring | $28.32 | 2019 | |
| Merck Sharp & Dohme LLC | $25.10 | 2025 | Zerbaxa |
| Genentech USA, INC. | $25.00 | 2025 | Xolair |
| Takeda Pharmaceuticals U.S.A., INC. | $19.85 | 2025 | Glassia |
| Novartis Pharmaceuticals Corporation | $18.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Easow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.